

## **Gregory S. Zaric**

Professor, Management Science, Ivey Business School  
Professor, Epidemiology and Biostatistics, Schulich School of Medicine and Dentistry  
Academic Director, MSc in Management, Ivey Business School  
Academic Director, Master of Management in Analytics, Ivey Business School  
Editor-in-Chief, Health Care Management Science  
Western University  
London, Ontario N6A 3K7  
(519) 661-3415  
[gzaric@ivey.uwo.ca](mailto:gzaric@ivey.uwo.ca)

### **EDUCATION**

**Ph.D.**, Industrial Engineering, Stanford University  
**M.S.**, Industrial Engineering, Stanford University  
**M.A.Sc.**, Management Science, University of Waterloo  
**B.Sc.**, Actuarial Science, University of Western Ontario

### **HONORS AND AWARDS**

2017 Finalist, Practice Prize Competition, Canadian Operational Research Society  
2016 The Bridge Award, Ivey Business School  
2012 J. Allyn Taylor & Arthur Mingay Chair in Management Science, Ivey School of Business  
2011 Best Short Course, Society for Medical Decision Making Annual Meeting  
2010 Best Short Course, Society for Medical Decision Making Annual Meeting  
2010 Lawrence G. Tapp Excellence in Teaching Award, Ivey School of Business, awarded by MBA class of 2010  
2009 3<sup>rd</sup> Place, INFORMS Annual Case Competition for the case “The Gold Claim at Sturgeon Lake”  
2008 Lawrence G. Tapp Excellence in Teaching Award, Ivey School of Business, awarded by MBA class of 2008  
2008 Research Excellence Award, International Society for Pharmacoeconomics and Outcomes Research (ISPOR)  
2008 Faculty Scholar, University of Western Ontario  
2007 M.B.A. `82 Faculty Fellowship, Ivey School of Business  
2006 Canada Research Chair in Health Care Management Science (renewed in 2011)  
2004 Premier’s Research Excellence Award, Ontario Ministry of Research and Innovation  
2002 David G. Burgoyne Award for Outstanding Commitment to Student Development, Ivey School of Business, awarded by undergraduate/HBA students  
2001 Pierskalla Award in Recognition of Excellence in Health Care Management Science, Institute for Operations Research and the Management Sciences (INFORMS) Health Applications Section

## BOOKS

1. **Zaric GS** (Editor), *Operations Research and Health Care Policy*, Springer, International Series in Operations Research & Management Science, Vol. 190, 2013 (ISBN 978-1-4614-6506-5).
2. Bell PC, **Zaric GS**, *Analytics for Managers with Excel*, Routledge, 2012 (ISBN-13 9780415622684).

## RESEARCH

### *Refereed Journal Articles*

1. Bamimore MA, Devlin RA, **Zaric GS**, Nash DM, Garg AX, Sarma S, The relationship between family physicians' remuneration mechanism and quality of care for persons with chronic kidney disease, submitted.
2. Bamimore MA, Devlin RA, **Zaric GS**, Garg AX, Sarma S, Impact of family physician payment schemes on follow-up care, mortality risk and avoidable hospitalizations in patients with congestive heart failure? Revision requested.
3. Critchley G, Cipriano LE, **Zaric GS**, Goldhaber-Fiebert JD, Coordinating multi-payer health care systems, revision requested.
4. Qu XM, Chen Y, **Zaric GS**,... Louie AV, Is SABR cost-effective in oligometastatic cancer? An economic analysis of the SABR-COMET randomized trial, *International Journal of Radiation Oncology, Biology, Physics*, S0360-3016(20)34645-9. doi: 10.1016/j.ijrobp.2020.12.001. (epub ahead of print)
5. Bamimore MA, Devlin RA, **Zaric GS**, Garg AX, Sarma S, Quality of diabetes care in blended fee-for-service and blended capitation payment systems, *Canadian Journal of Diabetes*, S1499-2671(20)30355-5. doi: 10.1016/j.jcjd.2020.09.002 (epub ahead of print).
6. Ghamat S, **Zaric GS**, Pun H, Care-coordination: Gain-sharing agreements in bundled payment models, *Production and Operations Management*, 2020, doi:10.1111/poms.13332. (epub ahead of print).
7. Some NH, Devlin RA, Mehta N, **Zaric GS**, Sarma S, Stirring the Pot: Switching from Blended Fee-For-Service to Blended Capitation Models of Physician Remuneration, *Health Economics*, 2020, doi: 10.1002/hec.4145. (epub ahead of print).
8. Some NH, Devlin RA, Mehta N, **Zaric GS**, Sarma S, Team-based Primary Care Practice and Physician's Services: Evidence from Family Health Teams and Non-Teams in Ontario, Canada, *Social Science and Medicine*, 264:113310. doi: 10.1016/j.socscimed.2020.113310. (epub ahead of print)
9. **Zaric GS**, How Risky is that Risk Sharing Agreement? Mean-Variance Tradeoffs and Unintended Consequences of Six Common Risk Sharing Agreements, *Medical Decision Making Policy & Practice*, 2021, 6:1, doi.org/10.1177/2381468321990404.
10. Hong M, Thind A, **Zaric GS**, Sarma S, The impact of the after-hours premium on emergency department utilization: Results of a retrospective cohort analysis from Ontario, Canada, *Canadian Medical Association Journal (CMAJ)*, 2021, 193(3):E85-E93. doi: 10.1503/cmaj.200277.

11. Reid GR, Stewart SL, Barwick M, Carter J, Leschied A, Neufeld RWJ, St. Pierre J, Tobon JI, Vingilis E, **Zaric GS**, Exploring patterns of service utilization within children's mental health agencies, *Journal of Child and Family Studies*, 2021, 30: 556-574. DOI 10.1007/s10826-020-01859-2.
12. Thavam T, Devlin RA, Thind A, **Zaric G**, Sarma A, The Impact of the Diabetes Management Incentive on Diabetes-related Services: Evidence from Ontario, Canada, *European Journal of Health Economics*, 2020, 21(9):1279-1293. doi: 10.1007/s10198-020-01216-6..
13. Hong M, Thind A, **Zaric GS**, Sarma S, The impact of improved access to after-hours primary care on emergency department and primary care utilization: A systematic review, *Health Policy*, 2020, 124(8):812-818, <https://doi.org/10.1016/j.healthpol.2020.05.015>.
14. Reid GR, Stewart SL, Barwick M, Carter J, Leschied A, Neufeld RWJ, St. Pierre J, Tobon JI, Vingilis E, **Zaric GS**, Predicting Patterns of Service Utilization within Children's Mental Health Agencies, *BMC Health Services Research*, 2019, 19:993, [doi.org/10.1186/s12913-019-4842-2](https://doi.org/10.1186/s12913-019-4842-2).
15. Some NH, Devlin RA, Mehta N, **Zaric G**, Li L, Shariff S, Belhadji B, Thind A, Garg A, Sarma S, Production of physician services under fee-for-service and blended fee-for-service: Evidence from Ontario, Canada, *Health Economics*, 2019, 28(12):1418-1434. doi: 10.1002/hec.3951.
16. Critchley G, **Zaric GS**, The impact of pharmaceutical marketing on market access, treatment coverage, pricing, and social welfare, *Health Economics*, 2019, 28(8): 1035-51, doi: 10.1002/hec.3903.
17. Hannouf MB, **Zaric GS**, Blanchette P, Brezden-Masley C, Paulden M, McCabe C, Raphael J, Brackstone M, Cost-effectiveness analysis of multigene expression profiling assays to guide adjuvant therapy decisions in women with invasive early-stage breast cancer, *Pharmacogenomics J*, 2019 May 27. doi: 10.1038/s41397-019-0089-x.
18. Kim CK, et al., Survival outcome differences based on treatment utilization and knowledge of primary tumour site for cancer of unknown Primary (CUP) and known primary patients in Ontario, Canada, *Current Oncology*, 2018 Oct;25(5):307-316. doi: 10.3747/co.25.4003. Epub 2018 Oct 31.
19. Ghamat S, **Zaric GS**, Pun H, Contracts to Promote Optimal Use of Optional Diagnostic Tests in Cancer Treatment, *Production and Operations Management*, 2018, 27(12), 2184-2200, <https://doi.org/10.1111/poms.12780>.
20. Cipriano LE, **Zaric GS**, Cost-effectiveness of naloxone kits in secondary schools, *Drug and Alcohol Dependence*, 2018, 192(Nov): 352-61, <https://doi.org/10.1016/j.drugalcdep.2018.08.003>.
21. Lebenbaum M, **Zaric GS**, Thind A, Sarma S, Trends in obesity and multimorbidity in Canada, *Preventive Medicine*, 2018, 116(Nov), 173-9, <https://doi.org/10.1016/j.ypmed.2018.08.025>.
22. Hannouf MB, Winquist E, Mahmud SM, Brackstone M, Sarma S, Rodrigues GB, Rogan PK, Hoch JS, **Zaric GS**, The potential clinical and economic value of primary tumour identification in metastatic cancer of unknown primary tumour: a population-based retrospective matched cohort study, *Pharmacoeconomics Open*, 2018 Sep 2(3), 255-270, doi: 10.1007/s41669-017-0051-2.

23. Rastpour A, Begen MA, Louie AV, **Zaric GS**, Variability of waiting times for the 4 most prevalent cancer types in Ontario: a retrospective population-based analysis, *CMAJ Open*, 2018 Jun 7;6(2):E227-E234. doi: 10.9778/cmajo.20170118.
24. Rodrigues FFR, **Zaric GS**, Stanford DA, Discrete event simulation model for planning Level 2 “step-down” bed needs using NEMS, *Operations Research in Health Care*, 2018, 17(June), 42-54, <https://doi.org/10.1016/j.orhc.2017.10.001>.
25. Mahjoub R, Odegaard F, **Zaric GS**, Evaluation of a pharmaceutical risk-sharing agreement when patients are screened for the probability of success, *Health Economics*, 2018, Jan;27(1):e15-e25, doi: 10.1002/hec.3522.
26. Hannouf MB, Winquist E, Mahmud SM, Brackstone M, Sarma S, Rodrigues GB, Rogan PK, Hoch JS, **Zaric GS**, The clinical significance of occult gastrointestinal primary tumours in metastatic cancer: a population retrospective cohort study, *Cancer Research and Treatment*, 2018, 50(1), 183-94, <https://doi.org/10.4143/crt.2016.532>.
27. Jacobs J, Yaquian E, Burke SM, Rouse M, **Zaric GS**, The Economic Impact of Workplace Wellness Programs in Canada: An evaluation of the evidence, *Occupational Medicine*, 2017, Aug 1;67(6):429-434. doi: 10.1093/occmed/kqx075.
28. Capan M, Khojandi A, Denton BT, Williams, KD, Ayer T, Chhatwal J, Kurt M, Lobo JM, Roberts MS, **Zaric G**, Zhang S, Schwartz JS, From Data to Improved Decisions: Operations Research in Healthcare Delivery, *Medical Decision Making*, 2017, 37(8), 849-59, doi: 10.1177/0272989X17705636.
29. Hannouf MB, Winquist E, Mahmud SM, Brackstone M, Sarma S, Rodrigues GB, Rogan PK, Hoch JS, **Zaric GS**, The clinical significance of difficult-to-diagnose gynecologic primary tumours in metastatic cancer, *Current Oncology*, 2017 Oct; 24(5):e368-e378. doi: 10.3747/co.24.3594.
30. Ozturk O, Begen MA, Zaric GS, A branch and bound algorithm for scheduling unit size jobs on parallel batching machines to minimize makespan, *International Journal of Production Research*, 2017, 55(6): 1815-1831, <http://dx.doi.org/10.1080/00207543.2016.1253889>.
31. Akhtar AO, Martin J, **Zaric GS**, Si FF, Hutnik,CM, Hodge WG, Comparison of Clinical Trial and Model-Based Cost Estimates In Glaucoma -The Case of Repeat Laser Trabeculoplasty In Ontario, *Journal of Hospital Administration*, 2017, 6(3), 46-57, DOI: <https://doi.org/10.5430/jha.v6n3p46>.
32. Yan X, **Zaric GS**, Influenza vaccine supply chain with vaccination promotion effort and its coordination, *IIE Transactions on Healthcare Systems*, 2017, 7(1): 53-72, <http://dx.doi.org/10.1080/19488300.2016.1272012>.
33. Babashov V, Aivas I, Begen MA, Cao JQ, Rodrigues G, D’Souza D, Lock M, **Zaric GS**, Reducing patient wait times for radiation therapy and improving treatment planning efficiency: a discrete-event simulation model, *Clinical Oncology*, 2017, 29(6):385-391. doi: 10.1016/j.clon.2017.01.039.
34. Hannouf MB, Winquist E, Mahmud SM, Brackstone M, Sarma S, Rodrigues GB, Rogan PK, Hoch JS, **Zaric GS**, Cost-effectiveness of using a microarray-based gene expression test to identify primary tumour versus Canadian clinical practice in patients with cancer of unknown primary, *The Pharmacogenomics Journal*, 2017, 17:286-300, doi: 10.1038/tpj.2015.94.
35. Babashov V, Begen MA, Mangel J, **Zaric GS**, Economic evaluation of brentuximab vedotin for persistent Hodgkin lymphoma, *Current Oncology*, 2017, 24(1):e6-e14. doi: 10.3747/co.24.3369.

36. Pendrith C, Thind A, **Zaric GS**, Sarma S, Financial Incentives and Cervical Cancer Screening Participation in Ontario's Primary Care Delivery Models, *Healthcare Policy*, 2016, 12(1): 116-128. doi:10.12927/hcpol.2016.24758.
37. Jacobs JC, Burke S, Rouse M, Sarma S, **Zaric GS**, Cardiovascular disease risk awareness and its association with preventive health behaviours: Evidence from a Sample of Canadian Workplaces, *Journal of Occupational and Environmental Medicine*, 2016, 58(5): 459-65. doi: 10.1097/JOM.0000000000000694
38. **Zaric GS**, Cost implications of precision medicine implemented through companion diagnostics, *Pharmacoeconomics*, 2016 Jul;34(7):635-44, doi: 10.1007/s40273-016-0388-x.
39. Nguyen TK, Goodman CD, Boldt RG, Warner A, Palma DA, Rodrigues GB, Lock MI, Mishra, MV, **Zaric GS**, Louie AV, Evaluations of health economics in radiation oncology: a systematic review, *Int J Radiat Oncol Biol Phys*, 2016, 94(5):1006-14. doi: 10.1016/j.ijrobp.2015.12.359.
40. Yan X and **Zaric GS**, Families of supply chain coordinating contracts in the presence of retailer effort, *International Journal of Production Economics*, 2016, 175: 213-225, doi:10.1016/j.ijpe.2016.01.011.
41. Coronado AC, **Zaric GS**, Martin J, Malvankar-Mehta M, Si FF, Hodge WH, Cost-effectiveness analysis of diabetic retinopathy screening with pharmacy-based tele-ophthalmology versus in-person eye examination, *CMAJ Open*, 4(1): E95-102, 2016, DOI:10.9778/cmajo.20150085.
42. Zur RM, **Zaric GS**, A Microsimulation Cost-Utility Analysis of Alcohol Screening and Brief Intervention to Reduce Heavy Alcohol Consumption in Canada, *Addiction*, 2016, 111(5):817–831, DOI: 10.1111/add.13201.
43. Enns EA, **Zaric GS**, Strike CJ, Jairam JA, Kolla G, Bayoumi AM, Potential cost-effectiveness of supervised injection facilities in Toronto and Ottawa, Canada, *Addiction*, 2016, 111(3):475-89. doi: 10.1111/add.13195.
44. Larose SL, Kpelitse KA, Campbell MK, **Zaric GS**, Sarma S, Does obesity influence labour market outcomes among working-age women? Evidence from Canadian longitudinal data, *Economics and Human Biology*, 2016, 20:26-41, doi: 10.1016/j.ehb.2015.09.007.
45. Pendrith C, Thind A, **Zaric GS**, Sarma S, Costs of Cervical Cancer Treatment: Estimates from Ontario, Canada, *Current Oncology*, 2016, 23(2): e109-115, doi: <http://dx.doi.org/10.3747/co.23.2598>.
46. McCarron CE Ernst S Cao JQ, **Zaric GS**, Population-based estimates of survival and cost for metastatic melanoma, *Current Oncology*, 2015 Oct; 22(5): 326–332, doi: 10.3747/co.22.2557.
47. Kim CK, Hannouf MB, Sarma S, Rodrigues GB, Rogan PK, Mahmud SM, Winquist E, Brackstone M, **Zaric GS**, Identification and survival outcomes of a cohort of patients with cancer of unknown primary in Ontario, Canada, *Acta Oncologica*, 2015 54(10):1781-7. doi: 10.3109/0284186X.2015.1020965.
48. Zhang H, **Zaric GS**, Using price-volume agreements to manage pharmaceutical leakage and off-label promotion, *European Journal of Health Economics*, 2015 Sep;16(7):747-61. doi: 10.1007/s10198-014-0626-0.
49. Sarma S, Devlin RA, Gilliland J, Campbell MK, **Zaric GS**, The Effect of Leisure-time Physical Activity on Obesity, Diabetes, High BP and Heart Disease among Canadians: Evidence from 2000/01 to 2005/06, *Health Economics*, 2015, 24(12): 1531-47, doi: 10.1002/hec.3106.

50. Reid GJ, Stewart M, **Zaric GS**, Carter JR, Neufeld RWJ, Tobon JI, Barwick M, Vingilis ER, Defining episodes of care in children's mental health using administrative data, *Administration and Policy in Mental Health and Mental Health Services Research*, 2015, 42(6):737-47 DOI 10.1007/s10488-014-0609-6.
51. Sarma S, **Zaric GS**, Campbell MK, Gilliland J, The Effect of Physical Activity on Adult Obesity: Evidence from Canadian NPHS Panel, *Economics and Human Biology*, 2014 Jul;14:1-21. doi: 10.1016/j.ehb.2014.03.002.
52. Ozturk O, Begen MA, **Zaric GS**, A branch and bound algorithm for makespan minimization of washing operations in hospital sterilization services, *European Journal of Operational Research*, 2014, 239(1), 214-226. doi: 10.1016/j.ejor.2014.05.014
53. Ewara, EM, **Zaric GS**, Welch S, Sarma S, Cost-effectiveness of first-line treatments for KRAS wild-type colorectal cancer patients, *Current Oncology*, 2014, 21(4):e541-50. doi: 10.3747/co.21.1837.
54. Hannouf MB, Xie B, Brackstone M, **Zaric GS**, Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in post-menopausal women with early-stage estrogen or progesterone-receptor-positive, axillary lymph-node positive breast cancer, *Pharmacoeconomics*, 2014, 32:135–147, doi: 10.1007/s40273-013-0115-9.
55. Mahjoub R, Odegaard F, **Zaric GS**, Health-based pharmaceutical pay-for-performance risk-sharing agreements, *Journal of the Operational Research Society (JORS)*, 2014, 65: 588–604. doi:10.1057/jors.2013.106
56. Fournier DL, **Zaric GS**, Neonatal intensive care unit bed optimization model for British Columbia, *Socio-Economic Planning Sciences*, 2013, 47(2):131-41, <http://dx.doi.org/10.1016/j.seps.2013.01.001>.
57. Delgado MK, Meng L, Mercer M, Pines J, Owens DK, **Zaric GS**, Reducing ambulance diversion at the hospital and regional level: A systematic review of insights from simulation models, *Western Journal of Emergency Medicine*, 2013 Sep;14(5):489-498, DOI: 10.5811/westjem.2013.3.12788.
58. Reid GJ, Stewart M, Vingilis E, Dozois DJA, Wetmore S, Dickie G, Jordan J, Osmun T, Wade T, Brown JB, **Zaric GS**, Randomized trial of distance-based treatment for young children with discipline problems seen in primary care, *Family Practice*, 2013, 30(1):14-24. doi: 10.1093/fampra/cms051.
59. Pitman R, Fisman D, **Zaric GS**, Postma MJ, Kretzschmar M, Edmunds J, Brisson M, Dynamic Transmission Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force, *Value in Health*, 2012 Sep-Oct;15(6):828-34, doi: 10.1016/j.jval.2012.06.011.
60. Pitman R, Fisman D, **Zaric GS**, Postma MJ, Kretzschmar M, Edmunds J, Brisson M, Dynamic Transmission Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force, *Med Decis Making*, 2012 Sep-Oct; 32(5):712-21.
61. Hannouf MB, Brackstone M, Xie B, **Zaric GS**, Evaluating the efficacy of current clinical practice of adjuvant chemotherapy in post-menopausal women with early-stage, estrogen- or progesterone-receptor-positive, one-to-three-positive axillary lymph-node, breast cancer, *Curr Oncol*, 2012 Oct;19(5):e319-28. doi: 10.3747/co.19.1038.
62. Hannouf MB, Xie B, Brackstone M, **Zaric GS**, Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage

- estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer, *BMC Cancer*, 2012, 12(1): 447, doi: 10.1186/1471-2407-12-447.
63. **Zaric GS**, Brennan A, Varenbut M, Daïter J, The cost of providing methadone maintenance treatment in Ontario, Canada, *American Journal of Drug and Alcohol Abuse*, 2012, 38(6): 559-66, doi:10.3109/00952990.2012.694518.
  64. Cipriano LE, Levesque BG, **Zaric GS**, Loftus EV, Sandborn WJ, Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease, (e-pub online) in *Inflammatory Bowel Diseases*, 2012 Jul;18(7):1240-8. doi: 10.1002/ibd.21862.
  65. Cipriano LE, **Zaric GS**, Owens DK, Brandeau ML, Cost effectiveness of screening for acute HIV and HCV infection in injection drug users, *PLoS One*, 2012, 7(9): e45176. doi:10.1371/journal.pone.0045176
  66. Hannouf MB, Sehgal C, Cao JQ, Mocanu JD, Winquist E, **Zaric GS**, Cost-effectiveness of adding cetuximab to platinum-based chemotherapy for first-line treatment of recurrent or metastatic head and neck cancer, *PLoS One*, 2012, 7(6): e38557, doi:10.1371/journal.pone.0038557.
  67. Zecevic A, Chesworth B, **Zaric GS**, Huang Q, Salmon A, McAuslan D, Welch R, Brunton D, Wright C, Hill J, King J, Estimating the cost of serious injurious falls in a Canadian acute care hospital, *Canadian Journal on Aging*, 2012, 31(2), 139-47, doi:10.1017/S0714980812000037.
  68. Cao JQ, Rodrigues G, Louie AV, **Zaric GS**, Systematic review of the cost-effectiveness of positron-emission tomography in staging of non-small-cell lung cancer and management of solitary pulmonary nodules, *Clinical Lung Cancer*, 2012, 13(3), 161-70, DOI:10.1016/j.clcc.2011.09.002.
  69. Xie B, DaSilva O, **Zaric GS**, Cost effectiveness analysis of the system-based approach to manage neonate jaundice and prevent kernicterus in Ontario, Canada, *Paediatrics & Child Health*. 2012, 17(1), 11-16.
  70. Malvankar-Mehta M, **Zaric GS**, Incentives for optimal allocation of HIV prevention resources in a multilevel model, *INFOR*, 2011, 49(4), 241-6, DOI: 10.3138/infor.49.4.241.
  71. Zhang H, **Zaric GS**, Pharmaceutical marketing and leakage under a price-volume agreement, *INFOR*, 2011, 49(4), 247-53, 10.3138/infor.49.4.247.
  72. Louie AV, Rodrigues G, Hannouf M, **Zaric GS**, Palma DA, Cao JQ, Yaremko BP, Malthaner R, Mocanu JD, Stereotactic body radiotherapy versus surgery for medically operable Stage I NSCLC: a Markov model based decision analysis, *International Journal of Radiation Oncology • Biology • Physics*, 2011, 81(4), 964-73, DOI:10.1016/j.ijrobp.2010.06.040.
  73. Louie AV, Rodrigues G, Hannouf M, Lagerwaard F, Palma, D, **Zaric GS**, Haasbeek C, Senan S, Withholding stereotactic radiotherapy in elderly patients with stage I non-small cell lung cancer and co-existing COPD is not justified: Outcomes of a Markov model analysis, *Radiotherapy and Oncology*, 2011, 99(2), 161-65, DOI:10.1016/j.radonc.2011.04.005
  74. Reid GJ, Cunningham CE, Tobon JI, Evans B, Stewart M, Brown JB, Lent B, Neufeld RW, Vingilis ER, **Zaric GS**, Shanley DC, Help-seeking for children with mental health problems: Parents' efforts and experiences, *Administration and Policy in Mental Health and Mental Health Services Research*, 2011, 38(5), 384-97. DOI: 10.1007/s10488-010-0325-9.

75. Zhang H, **Zaric GS**, Huang T, Optimal design of a pharmaceutical price-volume agreement under asymmetric information about expected market size, *Production and Operations Management*, 2011, 20(3):334–346. DOI: 10.1111/j.1937-5956.2011.01219.x.
76. Lasry A, Carter, MW, **Zaric GS**, Allocating funds for HIV/AIDS: The case of kwaDukuza, South Africa, *Health Policy and Planning*, 2011, 26:33-42. DOI: 10.1093/heapol/czq022.
77. Cipriano, LE, Barth WH Jr., **Zaric GS**, The cost effectiveness of routine screening for vasa previa at 18-20 weeks gestation, *British Journal of Obstetrics and Gynecology*, 2010, 17(9):1108-18. DOI: 10.1111/j.1471-0528.2010.02621.x.
78. Huang Q, Thind A, Dreyer JF, **Zaric GS**, The impact of ED admission delays on inpatient outcomes, *BMC Emergency Medicine*. 2010, 10:16. DOI:10.1186/1471-227X-10-16.
79. **Zaric GS** and Xie B, A comparison of two risk sharing agreements, *Value in Health*, 2009, 12(5): 838-845. DOI: 10.1111/j.1524-4733.2009.00510.x.
80. Dreyer JF, McLeod SM, Anderson CK, Carter MW, **Zaric GS**, Physician workload and the Canadian triage and acuity scale: Results from the predictors of workload in the emergency room (POWER) study, *Canadian Journal of Emergency Medicine*, 2009, 11(4): 321-329.
81. Brandeau ML, **Zaric GS**, Optimal investment in HIV prevention programs: More is not always better, *Health Care Management Science*, 2009, 12(1), 27–37. DOI 10.1007/s10729-008-9074-7.
82. Bayoumi AM, **Zaric GS**, The cost effectiveness of Vancouver’s supervised injection facility, *Canadian Medical Association Journal (CMAJ)*, 2008, 179(11), 1143-51. DOI:10.1503/cmaj.080808.
83. **Zaric GS**, Optimal drug pricing, limited use conditions and stratified net benefits for Markov models of disease progression, *Health Economics*, 2008, 17(11):1277-94. DOI: 10.1002/hec.1332.
84. Cipriano LE, Chesworth BM, Anderson CK, **Zaric GS**, An evaluation of strategies to reduce waiting times for total joint replacement in Ontario, *Medical Care*, 2008, 46(11):1177-1183.
85. Camm JD, Magazine MJ, Polak GG, **Zaric GS**, Scheduling parallel assembly lines to minimize a shared pool of labor, *IIE Transactions*, 2008, 40(8): 749-758.
86. **Zaric GS**, Bravata DM, Holty JC, McDonald KM, Owens DK, Brandeau ML, Modeling the logistics of response to anthrax bioterrorism, *Medical Decision Making*, 2008 28: 332-350.
87. **Zaric GS**, Bayoumi AM, Brandeau ML, Owens DK, The cost effectiveness of improved adherence to HAART, *Medical Decision Making*, 2008 28: 359-376.
88. Brandeau ML, **Zaric GS**, Freiesleben J, Edwards FL, Bravata DM, An ounce of prevention is worth a pound of cure: improving communication to reduce mortality during bioterrorism responses, *American Journal of Disaster Medicine*, 2008, 3(2): 65-78.
89. Lasry A, Carter, MW, **Zaric GS**, S4HARA: System for HIV/AIDS Resource Allocation, *Cost Effectiveness and Resource Allocation*, 2008, 6:7.
90. Cipriano LE, Chesworth BM, Anderson CK, **Zaric GS**, Predicting total joint replacement waiting times in Ontario, *Health Care Management Science*, 2007, 10(2): 195-215.



91. Cipriano LE, Rupar CA, **Zaric GS**, The cost-effectiveness of expanding newborn screening for up to 21 inherited metabolic disorders using tandem mass spectrometry: results from a decision-analytic model, *Value in Health*, 2007, 10(2): 83-97.
92. Lasry, A., **Zaric GS**, Carter MW, Multi-level resource allocation for HIV prevention: A model for developing countries, *European Journal of Operational Research*, 2007, 16(2): 786-799.
93. **Zaric GS**, Brandeau ML, A little planning goes a long way: Multi-level allocation of HIV prevention resources, *Medical Decision Making*, 2007, 27(1):71-81.\*  
\* This paper was the winner of the 2008 *ISPOR Research Excellence Award*.
94. **Zaric GS**, Hoch JS, Medical savings accounts: Opportunities for cost savings?, *International Transactions in Operational Research*, 2006, 13(6):493-513.
95. Bravata DM, **Zaric GS**, Holty JC, Brandeau ML, Wilhelm ER, McDonald KM, Owens DK, Reducing Mortality from anthrax bioterrorism: Strategies for stockpiling and dispensing medical and pharmaceutical supplies, *Biosecurity and Bioterrorism: Biodefense Strategy, Practice and Science*, 2006, 4(3):244-262.
96. **Zaric GS**, O'Brien BJ, Analysis of a pharmaceutical risk sharing agreement based on the purchaser's total budget, *Health Economics*, 2005, 14(8):793-803.
97. Brandeau ML, **Zaric GS**, deAngelis V, Improved allocation of HIV prevention resources: using information about program production functions, *Health Care Management Science*, 2005, 8(1): 19-28.
98. **Zaric GS**, The impact of ignoring population heterogeneity when Markov models are used in cost effectiveness analysis, *Medical Decision Making*, 2003, 23(5), 379-96.
99. **Zaric GS**, Resource allocation for control of infectious disease epidemics, *Comments on Theoretical Biology*, 2003, 8:475-496.
100. Brandeau ML, **Zaric GS**, Richter, A, Resource allocation for control of infectious diseases in multiple independent populations: Beyond cost-effectiveness analysis, *Journal of Health Economics*, 2003, 22(4):575-598.
101. **Zaric GS**, Brandeau, ML, Dynamic resource allocation for epidemic control in multiple populations, *Mathematical Medicine and Biology*, 2002, 19(4):235-255.
102. **Zaric GS**, Random vs. nonrandom mixing in network epidemic models, *Health Care Management Science*, 2002, 5(2):147-155.
103. Barnett, PG, **Zaric, GS**, and Brandeau, ML, The cost effectiveness of buprenorphine maintenance for opioid dependence, *Addiction*, 2001, 96(9): 1267-1278.
104. **Zaric GS**, Brandeau ML, Optimal investment in a portfolio of HIV prevention programs, *Medical Decision Making*, 2001, 21(5):391-408.\*  
\* This paper was the winner of the *Pierskalla Award* in Recognition of Research Excellence in Health Care Management Science from the INFORMS Health Applications Section in 2001.
105. **Zaric GS**, Brandeau ML, Resource allocation for epidemic control over short time horizons, *Mathematical Biosciences*, 2001, 171(1):33-58.
106. **Zaric GS**, Bayoumi AM, Brandeau ML, Owens DK, The cost effectiveness of voluntary prenatal and routine newborn HIV screening in the United States, *Journal of Acquired Immune Deficiency Syndromes*, 2000, 25:403-416.

107. **Zaric GS**, Brandeau ML, Barnett PG, Methadone maintenance treatment and HIV prevention: A cost-effectiveness analysis, *Management Science*, 2000, 46:1013-1031.
108. **Zaric GS**, Barnett PG, Brandeau ML, HIV Transmission and the cost-effectiveness of methadone maintenance, *American Journal of Public Health*, 2000, 90:1100-1111.
109. **Zaric GS**, Brandeau ML, Bayoumi AM, Owens DK, The effects of protease inhibitors on the spread of HIV and the development of drug-resistant HIV strains: A simulation study, *Simulation*, 1998, 71:262-275.

### ***Non-Refereed Articles***

1. **Zaric, GS**, New developments for the journal in 2020, *Health Care Management Science* 2020 23(4):481. doi: 10.1007/s10729-020-09531-3.
2. **Zaric GS**, Welcome message from the new editor, *Health Care Management Science*, 2020, 23(1).
3. Cochran JJ, Hardin JR, Ingolfsson A, **Zaric GS**, Online journal gets a makeover, *OR/MS Today*, 2008, 35(4).

### ***Book Chapters***

1. Hannouf MB, **Zaric GS**, Cost effectiveness analysis using registry and administrative data, in Zaric GS (ed.) *Operations Research and Health Care Policy*, Springer, International Series in Operations Research & Management Science, Vol. 190, 2013.
2. **Zaric GS**, Zhang H, Mahjoub R, Pharmaceutical Risk Sharing Agreements and Patient Access Schemes, in Zaric GS (ed.) *Operations Research and Health Care Policy*, Springer, International Series in Operations Research & Management Science, Vol. 190, 2013
3. **Zaric GS**, Cost effectiveness analysis, healthcare policy, and operations research models, *Encyclopedia of Operations Research and Management Science*, Cochran JJ (ed.), 2010, John Wiley & Sons, Inc.
4. **Zaric, GS**, 2004, Modeling the costs and effects of maintenance treatment for opiate addiction. In Sainfort, F., Brandeau, M., Pierskalla, W., eds., *Handbook of Operations Research/Management Science Applications in Health Care*, Kluwer Academic Publishers (Hillier International Series in OR/MS).

### ***Conference Proceedings***

1. Sun H, Pun H, Zaric GS, Value or Volume? A Comparison of Two Risk Sharing Approaches, *Proceedings of the Decision Sciences Institute Annual Meeting 2018* p. 2101-2114.
2. Mahjoub R, Odegaard F, **Zaric GS**, Health Economic Evaluation Of A Pay-For-Performance Risk-Sharing Agreement. *Operational Research Applied to Health Services (ORAHS) 2013 Conference Proceedings*, Edited by T. Cayirli, M. M. Gunal, E. D. Gunes and E. L. Ormeci, 2013.
3. Zhang H, **Zaric GS**, Promotion and Leakage under a Pharmaceutical Price-Volume Agreement, *International perspectives on operations research and health*

- care. Proceedings of the 34<sup>th</sup> Annual Conference on Operational Research Applied to Health Services, Edited by J Blake and M Carter, Toronto, 2008.
4. Malvankar M, **Zaric GS**, Incentives for Optimal Multi-level Allocation of HIV Prevention Resources, International perspectives on operations research and health care. Proceedings of the 34<sup>th</sup> Annual Conference on Operational Research Applied to Health Services, Edited by J Blake and M Carter, Toronto, 2008.
  5. Lasry A, **Zaric GS**, Carter MW, Resource allocation for HIV prevention in a multi-level decision making framework. Proceedings of the 29th Meeting of the European Working Group on Operational Research Applied to Health Services. Edited by M. Dlouhý. Prague, Czech Republic: ORAHS, 2003.
  6. **Zaric GS**, Brandeau ML, Bayoumi AM, Owens DK, Simulating the effects of protease inhibitors on the HIV epidemic: Treatment, compliance, and drug resistance, In Anderson JG, Katzper M, Eds. Proceedings of the 1998 Medical Sciences Simulation Conference. 1998 Western Multiconference. Society for Computer Simulation, San Diego, CA, January 11-14, 1998, 65-72.

### **Reports**

1. Bayoumi AM and Strike C (co-principal investigators), Jairam J, Watson T, Enns E, Kolla G, Lee A, Shepherd S, Hopkins S, Millson M, Leonard L, **Zaric G**, Luce J, Degani N, Fischer B, Glazier R, O'Campo P, Smith C, Penn R, Brandeau M. Report of the Toronto and Ottawa Supervised Consumption Assessment Study, 2012. Toronto, Ontario: St. Michael's Hospital and the Dalla Lana School of Public Health, University of Toronto.  
(<http://www.catie.ca/sites/default/files/TOSCA%20report%202012.pdf>)
2. Zecevic A., McAuslan D., Chesworth B., **Zaric G**. Salmon A., Welch R., Brunton D., Wright C., Hill J-A., King J. Cost of serious injurious in-hospital falls. Final report to the RNAO, May 2009.
3. Reid, G. J., Brown, J. B., Evans, B., Cunningham, C. E., Lent, B., Stewart, M. A., Neufeld, R. W., Vingilis, E. R., **Zaric, G.**, Shanley, D., Lowe, H., Mazaheri, N., and Ure, G. Help – I need somebody: The experiences of families seeking treatment for children with psychosocial problems and the impact of delayed or deferred treatment. 2006. Ottawa, ON, Canadian Health Services Research Foundation.
4. Anderson CK, Bourne RB, Chesworth BM, Cipriano LE, Warner S, **Zaric GS**, Looking Forward to 2015: Comparing Wait List Management Options, Ontario Joint Replacement Registry, March 2006.
5. Dreyer JF, **Zaric GS**, Anderson CK, Carter MW, McLeod, SM, Predictors of Workload in the Emergency Room: The POWER Study, Phase I, Submitted to the Ontario Ministry of Health and Long Term Care, October 2005.
6. Bravata DM, McDonald K, Owens DK, Wilhelm ER, Brandeau ML, **Zaric GS**, Holty J-EC, Liu H, Sundaram V, Regionalization of Bioterrorism Preparedness and Response (Evidence Report/Technology Assessment No. 96 prepared by Stanford-University of California San Francisco Evidence-based Practice Center under Contract No. 290-02-0017). AHRQ Publication No. 04-E016-1 (Summary), 04-E016-2 (Full Report). Rockville, MD: Agency for Healthcare Research and Quality, 2004.

## **RESEARCH GRANTS (as PI or co-PI)**

1. Novel Contractual Arrangements in the Pharmaceutical Industry, Natural Sciences and Engineering Research Council of Canada (NSERC) Discovery Grant, 2017-2022, \$205,000. (2017-04089)
2. An economic evaluation of bevacizunab to treat glioblastoma multiforme, Canadian Centre for Applied Research in Cancer Control, 2012-2014, \$26,500.
3. Optimal Pricing, Purchasing, and Co-Development with Applications in Public and Private Sector Pharmaceutical Management, Natural Sciences and Engineering Research Council of Canada (NSERC) Discovery Grant, 2012-2017, \$140,000.
4. Optimal Pricing, Purchasing, and Co-Development with Applications in Public and Private Sector Pharmaceutical Management, Natural Sciences and Engineering Research Council of Canada (NSERC) Discovery Accelerator Supplement, 2012-2015, \$120,000. (429676-2012).
5. A personalised approach to the treatment of malignant melanoma: An economic evaluation of ipilimumab, Canadian Centre for Applied Research in Cancer Control, 2012-2013, \$45,000.
6. Economic Evaluation of Nalmefene for the Treatment of Alcoholism, University of Western Ontario Academic Development Fund, \$8,500, 2011-2012.
7. Economic evaluation of tests to reveal the source of cancers of unknown primary (with Co-Is M Brackstone, J Hoch, G Rodrigues, P Rogan and S Sarma), Canadian Institutes of Health Research, \$173,829, 2011-2014. (#231890)
8. Cost effectiveness of Oncotype in Ontario: should OHIP provide coverage? (with co-PI Bin Xie), University of Western Ontario Academic Development Fund, \$8500, 2009 (FG08-51).
9. Optimal allocation of public sector resources, Natural Sciences and Engineering Research Council of Canada (NSERC), \$106,000, 2007-2012 (228649-2007).
10. Economic analysis of methadone programs in Ontario, Ontario Addiction Treatment Centres, \$29,100, 2006-2008.
11. Biotech Research Grant, Ivey Biotech MBA Program, \$5,000, 2005.
12. The Impact of Risk Sharing Agreements on Drug Pricing and Access, Premier's Research Excellence Award (PREA), \$150,000, 2004-2009 (PREA 10/3453).
13. Predictors of Workload in the Emergency Room: The POWER Study (with Co-Principal Investigator Jonathan F. Dreyer), Ontario Ministry of Health and Long Term Care, \$399,000, 2003-2007.
14. Resource Allocation and Population Diversity, Natural Sciences and Engineering Research Council of Canada (NSERC), \$105,000, 2002-2007.
15. M.B.A. '80 Faculty Fellowship, Richard Ivey School of Business, 2001-Present, \$2,500/year.

## **TEACHING**

Ivey Business School:

- Business 9071, Ivey Analytics Lab (MSc)
- Business 9087, 9088, Programming Skills 1 and 2 (MSc)
- Business 9882, Health Care Management Science (PhD)
- Business 9470, Introduction to Data Science (MBA)
- Business 9457, Health Care Analytics (MBA)

- Business 9551, Competing with Analytics (EMBA)
- Business 9401 (formerly 545), Decision Making with Analytics (MBA)
- Business 9434, Competing with Analytics (MBA)
- Business 9414 (formerly 573), Pharmacoeconomics (MBA)
- Business 3316, Decision Making with Analytics, (HBA)
- Business 467/667, End User Models, (HBA)
- Business 486, Financial Models in Excel, (HBA)
- Business 816, Ph.D. Special Fields (PhD)
- Preparatory Knowledge Program, Quant Module (MBA)

Stanford University:

- Industrial Engineering 180, IE Senior Project, Stanford University, 1998

### ***Graduate Student Supervision***

#### **Master's Students – Supervisor or Co-Supervisor**

- Aren Fischer (M.Sc. Epidemiology and Biostatistics, 2016)  
 “Cost Effectiveness of Bevacizumab for Glioblastoma Multiforme”
- Chong (Danny) Kim (M.Sc. Epidemiology and Biostatistics, 2015)  
 “Survival and Cost Among Patients with Cancer of Unknown Primary in Ontario”
- Rodney Tembo (M.Sc. Applied Mathematics, 2014)  
 “Co-Development Contracts for Companion Diagnostics”
- Emmanuel Ewara (M.Sc. Epidemiology and Biostatistics, 2012) (co-supervisor)  
 “The Cost-Effectiveness of Combination Treatment Consisting of Either Cetuximab or Panitumumab Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as First-Line Treatment for KRAS Wild-Type Metastatic Colorectal Cancer Patients in Ontario”
- Vusal Babashov (M.Sc., Epidemiology and Biostatistics, 2012) (co-supervisor)  
 “Preliminary economic evaluation of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: An “early look” model based on Phase II results”
- Muhammad Ali (M.Sc., Epidemiology and Biostatistics, 2011)  
 “Cost Effectiveness Analysis of Anti-EGFR Monoclonal Antibodies”
- Ching Huang (M.Sc., Epidemiology and Biostatistics, 2009)  
 “Emergency room delays prior to admission and in-hospital health and economic outcomes”
- C. Elizabeth McCarron (M.Sc., Epidemiology and Biostatistics, 2006) (co-supervisor)  
 “Blood conservation: An economic evaluation”

#### **Master's Students – Committee Member**

- Thaksha Thavam (M.Sc. Epidemiology and Biostatistics)
- Yujie Chen (M.Sc. Student, Epidemiology and Biostatistics)
- Badria Eid AlJohani (M.Sc. Surgery)
- Ciara Pendrith (M.Sc. Epidemiology and Biostatistics, 2014)
- Ahmad Omar Akhtar (M.Sc. Epidemiology and Biostatistics, 2014)
- Andrea Coronado (M.Sc. Epidemiology and Biostatistics, 2014)

Samantha LaRose (M.Sc. Epidemiology and Biostatistics, 2014)  
Michael Lebenbaum (M.Sc. Epidemiology and Biostatistics, 2013)

### **Doctoral Students – Supervisor or Co-Supervisor**

Hossein Reihani (Ph.D. Student, Business Administration)  
Hongmei Sun (Ph.D. Student, Business Administration, 2020)  
Gregory Critchley (Ph.D. Student, Business Administration, 2019)  
Felipe Rodrigues (Ph.D. 2018, Business Administration) (co-supervisor)  
Salar Ghamat (Ph.D. 2017, Business Administration) (co-supervisor)  
    “Three Essays on Incentive Problems of Parties with Potential Conflict of Interest”  
Azaz Bin Sharif (Ph.D. Statistical and Actuarial Sciences, 2016) (co-supervisor)  
    “Probability Models for Health Care Operations with Application to Emergency Medicine”  
Malek Hannouf (Ph.D., Epidemiology and Biostatistics, 2014)  
    “Economic evaluation of genetic testing for cancer treatment decision making”  
Reza Mahjoub (Ph.D., Business Administration, 2014) (co-supervisor)  
    “Pharmaceutical Risk Sharing Agreements”  
Monali Malvankar (Ph.D., Business Administration, 2010) (co-supervisor)  
    “Optimal incentives for efficient allocation of HIV prevention and treatment resources”  
Hui Zhang (Ph.D., Business Administration, 2008)  
    “Risk sharing models and pharmaceutical purchasing”  
Arielle Lasry (Ph.D., Industrial Engineering, 2006) (co-supervisor)  
    (University of Toronto)  
    “Resource allocation for HIV/AIDS in Sub-Saharan Africa”

### **Doctoral Students – Committee Member**

Mary Bamimore (Ph.D. Epidemiology and Biostatistics, 2021)  
Michael Hong (M.Sc. Epidemiology and Biostatistics)

### **Post-Doctoral Fellows**

Hosein Zare (2018-Present)  
Bahman Naderi (2018-2019)  
Estefania Ruiz Vargas (2016-2017)  
Josephine Jacobs (2014)  
Sepehr Nemati (2014-2016)  
Jackie Marsh (2014-2015)  
Anh Tran (2014-2015)  
Onur Ozturk (2012-2013)  
Jianbo Qian (2012-2015)  
Elizabeth McCarron (2012-2014)  
Richard Zur (2011-2012)  
Sakine Batun (2011-2012)

## CASE WRITING

1. A high-level overview of linear regression, Ivey 9B10E002.
2. HomeZilla: Attracting Homebuyers through Better Photos (with H. Sun), Ivey 9B16E029.
3. The credit card offer, Ivey 9B16E006.
4. A note on dynamic optimization, Ivey 9B15E016.
5. Introduction to Microsoft Excel, Ivey 9B16E009 (with L. Cipriano)
6. Basic mathematical operations in Microsoft Excel, Ivey 9B16E010 (with K. MacLean and L. Cipriano)
7. Using absolute and relative references in Microsoft Excel, Ivey 9B16E011 (with K. MacLean and L. Cipriano)
8. Good modeling practices in Microsoft Excel, Ivey 9B16E012 (with K. MacLean and L. Cipriano)
9. Using logic functions in Microsoft Excel, Ivey 9B16E013 (with K. MacLean, J. Lyons and L. Cipriano)
10. Introductory descriptive statistics in Microsoft Excel, Ivey 9B16E014 (with K. MacLean and L. Cipriano)
11. Histograms and the normal distribution in Microsoft Excel, Ivey 9B16E015 (with K. MacLean and L. Cipriano)
12. Using data tables in Microsoft Excel, Ivey 9B16E017 (with K. MacLean and L. Cipriano)
13. Using goal seek in Microsoft Excel, Ivey 9B16E018 (with K. MacLean and L. Cipriano)
14. Advanced Logic Functions in Microsoft Excel, Ivey 9B16E016 (with K. MacLean, J. Lyons and L. Cipriano)
15. Radiation treatment machine capacity planning at Cancer Care Ontario, Ivey 9B15E014 (with J. Wang)
16. Vanderbilt university medical center: elective surgery schedule, Ivey 9B15E011 (with L. Cipriano, V. Tiwari and S. Sandberg)
17. C&D Hotel, Xiamen, Ivey 9B15D002 (with C. Wu, H. Pun and D. Chen)
18. Barclays' Metals and Mining, Ivey 9B13E009.
19. Ambulance Diversion at San Francisco General Hospital, Ivey 9B13E005 (with L. Meng).
20. Paying for eculizumab, Ivey 9B11E017 (with R. Zur).
21. British Columbia NICU bed allocation, Ivey 9B10E016 (with D. Fournier)
22. Difficult choices – An introduction to cost effectiveness analysis, Ivey 9B10E007.
23. Shopping Lanes (with M. Leff)
24. The Gold Claim at Sturgeon Lake, Ivey 9B09E018 (with P. Bell).
25. The challenge of access to oncology drugs in Canada, Ivey 9B09E020 (with C. Sehgal).
26. Monte Carlo simulation in Excel without using add-ins, Ivey 9B09E004.
27. A note on statistics and the law, Ivey 9B09E001, (with I. Funez).
28. Western Day Care Centre: The Emery Street Expansion, Ivey 9B08E006 (with C. Xu).
29. Pulling the Goalie in Hockey, Ivey 9B08E011 (with M. Leff).

30. Williams Coffee Pub: The Franchising Opportunity, Ivey 9B07E020 (with H. Zhang).
31. Elite Rent-a-Car, Ivey 9B07E011 (with J. Mitchell).
32. Professor Gets Engaged, Ivey 9B06E017 (with M. Leff).
33. Springbank Drive, Ivey 9B06E006 (with L. MacDonald).
34. Ernst and Young: The Western Bank Audit, Ivey 9B06E005.
35. The Ontario Formulary, Ivey 9B06E001 (with S. R. Frey).
36. Note on Statistics for Clinical Trials (with S. Stewart and J. Hatch).
37. Acushnet Canada Inc., The Bonded Warehouse Initiative, Ivey 9B05E012 (with I. Friedman).
38. Solnyx Pharmaceuticals: The Atoxeril Trial, Ivey 9B05E013 (with S. Stewart and J. Hatch).
39. Canning Consultants: The OPAC Assessment, Ivey 9B05E006.
40. Dr. Zidar, Ivey 9B04E026.
41. The Normal Distribution and the NCAA Tournament, Ivey 9B04E020 (with C. Anderson).
42. London Economic Development Corporation, Ivey 9B02E008 (with S. Allibhai).
43. Opion, Ivey 9B02E003 (with S. Allibhai).
44. Palmyra Trading Company, Ivey 9B01E022 (with A. Awaysheh).
45. HIV and Methadone, Ivey 9B00E014 (with R. McGowan).
46. Lansink Appraisals, Ivey 9B00E013.

## **ACADEMIC AND PROFESSIONAL SERVICE**

### ***Editorial Work***

- Editor in Chief, Health Care Management Science, 2019-Present
- Associate Editor, *Operations Research*, 2006-Present
- Senior Editor, *Production and Operations Management*, 2010-Present
- Editorial Board, *EURO Journal on Decision Processes*, 2013-Present
- Associate Editor, *Socio-Economic Planning Sciences*, 2011-2013
- Editorial Board, *Medical Decision Making*, 2005-2008
- Associate Editor for Cases, *INFORMS Transactions on Education*, June 2003-2008

### ***Pharmacoeconomic Review Activities***

- Member, Ontario Steering Committee for Cancer Drugs (OSCCD), 2018-Present
- Ad-hoc pharmacoeconomic reviewer for CADTH, pCODR and CED

## **PROFESSIONAL AFFILIATIONS**

CORS – Canadian Operations Research Society  
 INFORMS – Institute for Operations Research and Management Science  
 SMDM – Society for Medical Decision Making